A Phase I Study of Inhaled GM-CSF in the Treatment of Respiratory Virus-associated Severe Pneumonia

Trial Profile

A Phase I Study of Inhaled GM-CSF in the Treatment of Respiratory Virus-associated Severe Pneumonia

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2015

At a glance

  • Drugs Sargramostim (Primary)
  • Indications Adult respiratory distress syndrome
  • Focus Adverse reactions
  • Acronyms iGRASP
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top